eMedicine Specialties > Dermatology > Malignant Neoplasms

Premalignant Fibroepithelial Tumor (Pinkus Tumor): Follow-up

Author: Darius Mehregan, MD, Associate Professor, Hermann Pinkus Chairman of Dermatology, Department of Dermatology, Wayne State University; Clinical Associate Professor of Pathology, University of Toledo; Dermatopathologist, Pinkus Laboratory; Consulting Staff, J Dingell Veterans Affairs Medical Center
Coauthor(s): Jennifer Michelle Heyl, MD, Staff Physician, Department of Dermatology, Wayne State University School of Medicine
Contributor Information and Disclosures

Updated: Mar 27, 2009

Follow-up

Further Outpatient Care

The development of one nonmelanoma skin cancer predisposes the patient to a higher risk for developing a second cancer. Therefore, close follow-up care is recommended to monitor for the development of similar tumors at the site of treatment and at alternate locations. Current recommendations suggest yearly skin examinations by a dermatologist.

Deterrence/Prevention

Encourage all patients to use sunscreens with a sun protective factor of at least 15. Avoidance of sun exposure during the peak intensity hours of the day, from 10 am to 3 pm, is also recommended.

Complications

Fibroepithelioma of Pinkus can be classified as malignant with a low metastatic potential.

Prognosis

The treatments discussed in Surgical Care yield 5-year disease-free intervals in 80-90% of patients with basal cell skin cancer. With procedures, such as Mohs surgery, 5-year disease-free intervals can be expected in 98% of patients. Because the fibroepithelioma of Pinkus is a variant of basal cell skin cancer, expected disease-free intervals should closely match those of other forms of basal cell carcinoma.

Patient Education

Educate all patients with basal cell carcinoma in the proper use of sunscreens, the dangers of tanning, and the avoidance of sun during the peak hours of midday.

 
Acknowledgments

The authors and editors of eMedicine gratefully acknowledge the contributions of previous author, David Pegouske MD, to the development and writing of this article. 



More on Premalignant Fibroepithelial Tumor (Pinkus Tumor)

Overview: Premalignant Fibroepithelial Tumor (Pinkus Tumor)
Differential Diagnoses & Workup: Premalignant Fibroepithelial Tumor (Pinkus Tumor)
Treatment & Medication: Premalignant Fibroepithelial Tumor (Pinkus Tumor)
Follow-up: Premalignant Fibroepithelial Tumor (Pinkus Tumor)
References
[ CLOSE WINDOW ]

References

  1. Pinkus H. Premalignant fibroepithelial tumors of skin. AMA Arch Derm Syphilol. Jun 1953;67(6):598-615. [Medline].

  2. Matsumura Y, Nishigori C, Yagi T, Imamura S, Takebe H. Characterization of p53 gene mutations in basal-cell carcinomas: comparison between sun-exposed and less-exposed skin areas. Int J Cancer. Mar 15 1996;65(6):778-80. [Medline].

  3. Aszterbaum M, Rothman A, Johnson RL, Fisher M, Xie J, Bonifas JM, et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol. Jun 1998;110(6):885-8. [Medline].

  4. Stern JB, Haupt HM, Smith RR. Fibroepithelioma of Pinkus. Eccrine duct spread of basal cell carcinoma. Am J Dermatopathol. Dec 1994;16(6):585-7. [Medline].

  5. Pan Z, Huynh N, Sarma DP. Fibroepithelioma of pinkus in a 9-year-old boy: a case report. Cases J. 2008;1(1):21. [Medline].

  6. Hartschuh W, Schulz T. Merkel cell hyperplasia in chronic radiation-damaged skin: its possible relationship to fibroepithelioma of Pinkus. J Cutan Pathol. Sep 1997;24(8):477-83. [Medline].

  7. Bryant J. Fibroepithelioma of Pinkus overlying breast cancer. Arch Dermatol. Mar 1985;121(3):310. [Medline].

  8. Warner TF, Burgess H, Mohs FE. Extramammary Paget's disease in fibroepithelioma of Pinkus. J Cutan Pathol. Oct 1982;9(5):340-4. [Medline].

  9. Heymann WR, Soifer I, Burk PG. Penile premalignant fibroepithelioma of Pinkus. Cutis. May 1983;31(5):519-21. [Medline].

  10. Zalaudek I, Leinweber B, Ferrara G, Soyer HP, Ruocco E, Argenziano G. Dermoscopy of fibroepithelioma of pinkus. J Am Acad Dermatol. Jan 2005;52(1):168-9. [Medline].

  11. Naeyaert JM, Pauwels C, Geerts ML, Verplancke P. CD-34 and Ki-67 staining patterns of basaloid follicular hamartoma are different from those in fibroepithelioma of Pinkus and other variants of basal cell carcinoma. J Cutan Pathol. Nov 2001;28(10):538-41. [Medline].

  12. Katona TM, Ravis SM, Perkins SM, Moores WB, Billings SD. Expression of androgen receptor by fibroepithelioma of Pinkus: evidence supporting classification as a basal cell carcinoma variant?. Am J Dermatopathol. Feb 2007;29(1):7-12. [Medline].

  13. Barr RJ, Herten RJ, Stone OJ. Multiple premalignant fibroepitheliomas of Pinkus: a case report and review of the literature. Cutis. Mar 1978;21(3):335-7. [Medline].

  14. Jaffe ES. Premalignant fibroepithelioma of Pinkus. Arch Dermatol. 1964;89:768.

  15. Lever WF, Schaumberg-Lever G. Fibroepithelioma. In: Histopathology of the Skin. Philadelphia, Pa: Lippincott; 1983:570.

  16. Mehregan AH. Proliferation of sweat ducts in certain diseases of the skin. Am J Dermatopathol. 1981;3(1):27-31. [Medline].

  17. Val-Bernal JF, Gómez-Ortega JM, Fernández-Llaca H, Gómez-Román JJ. Fibroepithelioma of pinkus with tumor giant cells. Am J Dermatopathol. Aug 2002;24(4):336-9. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

premalignant fibroepithelioma of Pinkus, fibroepithelioma of Pinkus, Pinkus tumor, basal cell carcinoma

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Darius Mehregan, MD, Associate Professor, Hermann Pinkus Chairman of Dermatology, Department of Dermatology, Wayne State University; Clinical Associate Professor of Pathology, University of Toledo; Dermatopathologist, Pinkus Laboratory; Consulting Staff, J Dingell Veterans Affairs Medical Center
Darius Mehregan, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society of Dermatopathology, International Society of Dermatology, International Society of Dermatopathology, Phi Beta Kappa, and Society for Investigative Dermatology
Disclosure: Nothing to disclose.

Coauthor(s)

Jennifer Michelle Heyl, MD, Staff Physician, Department of Dermatology, Wayne State University School of Medicine
Disclosure: Nothing to disclose.

Medical Editor

Maureen B Poh-Fitzpatrick, MD, Professor Emerita of Dermatology and Special Lecturer, Columbia University; Professor of Medicine (Dermatology), University of Tennessee
Maureen B Poh-Fitzpatrick, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and New York Academy of Medicine
Disclosure: Nothing to disclose.

Pharmacy Editor

Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University School of Medicine; Consulting Staff, Mountain View Dermatology, PA
Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, Texas Dermatological Society, and Texas Medical Association
Disclosure: Nothing to disclose.

Managing Editor

Rosalie Elenitsas, MD, Herman Beerman Associate Professor of Dermatology, University of Pennsylvania School of Medicine; Director, Penn Cutaneous Pathology Services, Department of Dermatology, University of Pennsylvania Health System
Rosalie Elenitsas, MD is a member of the following medical societies: American Academy of Dermatology and American Society of Dermatopathology
Disclosure: Nothing to disclose.

CME Editor

Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology
Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds None; Genentech Consulting fee Consulting; Centocor Consulting fee Consulting; Centocor Grant/research funds None; Covance Consulting fee Consulting; Shire  Consulting

Chief Editor

William D James, MD, Paul R Gross Professor of Dermatology, University of Pennsylvania School of Medicine; Vice-Chair, Program Director, Department of Dermatology, University of Pennsylvania Health System
William D James, MD is a member of the following medical societies: American Academy of Dermatology and Society for Investigative Dermatology
Disclosure: elsevier Royalty Other; american college of physicians Honoraria Other

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.